Personal Home Page

http://www.icr.ac.uk/research/research_profiles/2825.shtml

Articles in Scholarly Journals [Incomplete List]

1. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma
   Cancer, vol. 112, no. 7, pp. 1585–1591, 2008
2. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
   Cancer Chemotherapy and Pharmacology, 2008
3. Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital
   European Journal of Cancer, vol. 44, no. 7, pp. 978–982, 2008
4. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
   British Journal of Cancer, vol. 98, no. 6, Article ID 6604218, 4 pages, 2008
5. A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
   Clinical Cancer Research, vol. 14, no. 7, pp. 2075–2081, 2008
6. Biomarkers In Early Clinical Trials: the Committed and the Skeptics
   Clinical Cancer Research, vol. 14, no. 8, pp. 2512–2512, 2008
7. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
   Molecular Cancer Therapeutics, vol. 7, no. 4, pp. 737–739, 2008
8. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
   Journal of Clinical Oncology, vol. 26, no. 10, pp. 1588–1595, 2008
9. Imatinib for Patients With Liver or Kidney Dysfunction: No Need to Modify the Dose
   Journal of Clinical Oncology, vol. 26, no. 4, pp. 521–522, 2008
10. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
    Journal of Clinical Oncology, vol. 26, no. 10, pp. 1603–1610, 2008
11. Humors of Tumors: Potential for Interaction Between Cancer Type and Treating Oncologist's Personality?
    Journal of Clinical Oncology, vol. 26, no. 9, pp. 1566–1567, 2008
12. Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors
    Journal of Clinical Oncology, vol. 25, no. 29, pp. 4603–4609, 2007
13. Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
    Cancer Research, vol. 67, no. 7, pp. 3239–3253, 2007
14. HDAC Inhibitors and Cardiac Safety
    Clinical Cancer Research, vol. 13, no. 3, pp. 1068–1068, 2007
15. Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
    Clinical Cancer Research, vol. 13, no. 20, pp. 6187–6194, 2007
16. Participation of patients with gynecological cancer in phase I clinical trials: Two years experience in a major cancer center
    Gynecologic Oncology, vol. 104, no. 3, pp. 551–556, 2007
17. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 43, no. 2, pp. 308–315, 2007
18. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
    European Journal of Cancer, vol. 43, no. 6, pp. 974–978, 2007
19. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
    The Lancet Oncology, vol. 8, no. 7, pp. 595–602, 2007
20. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib
    Pediatric Blood & Cancer, vol. 50, no. 2, pp. 386–388, 2007
21. Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG
    Targeted Oncology, vol. 1, no. 1, pp. 54–55, 2006
22. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    European Journal of Cancer, vol. 42, no. 8, pp. 1093–1103, 2006
23. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
    European Journal of Cancer, vol. 42, no. 14, pp. 2277–2285, 2006
24. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas
    European Journal of Cancer, vol. 42, no. 14, pp. 2303–2309, 2006
25. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    The Lancet, 2006
26. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models
    Cancer Research, vol. 66, no. 1, pp. 427–434, 2006
27. A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma
    Sarcoma, vol. 2006, Article ID 41080, 5 pages, 2006
28. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
    British Journal of Cancer, vol. 96, no. 1, Article ID 6603509, 8 pages, 2006
29. A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies
    Clinical Cancer Research, vol. 12, no. 9, pp. 2841–2848, 2006
30. How to Treat the Ewing's Family of Sarcomas in Adult Patients
    The Oncologist, vol. 11, no. 1, pp. 65–72, 2006
31. The development and application of imatinib
    Expert Opinion on Drug Safety, vol. 4, no. 2, pp. 183–191, 2005
32. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
    Journal of Clinical Oncology, vol. 23, no. 18, pp. 4152–4161, 2005
33. Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study
    Journal of Clinical Oncology, vol. 23, no. 24, pp. 5795–5804, 2005
34. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
    British Journal of Cancer, vol. 92, no. 9, Article ID 6602550, 11 pages, 2005
35. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points
    British Journal of Cancer, vol. 93, no. 8, Article ID 6602797, 7 pages, 2005
36. Soft-Tissue Sarcomas in Adults
    New England Journal of Medicine, vol. 353, no. 7, pp. 701–711, 2005
37. Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
    Clinical Cancer Research, vol. 11, no. 19, pp. 7023–7032, 2005
38. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital
    Annals of Oncology, vol. 16, no. 3, pp. 437–444, 2005
39. Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    Annals of Oncology, vol. 16, no. 4, pp. 566–578, 2005
40. ZD9331: discovery to clinical development
    Anti-Cancer Drugs, vol. 16, no. 1, pp. 1–9, 2005
41. SURGERY FOR GASTROINTESTINAL STROMAL TUMOUR IN THE POST-IMATINIB ERA
    ANZ Journal of Surgery, vol. 75, no. 3, pp. 165–172, 2005
42. Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas
    Hematology/Oncology Clinics of North America, vol. 19, no. 3, pp. 489–500, 2005
43. RECIST WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma
    European Journal of Cancer, vol. 41, no. 10, pp. 1426–1430, 2005
44. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
    European Journal of Cancer, vol. 41, no. 12, pp. 1751–1757, 2005
45. Differential sensitivity of liposarcoma subtypes to chemotherapy
    European Journal of Cancer, vol. 41, no. 18, pp. 2853–2860, 2005
46. Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks
    Investigational New Drugs, vol. 24, no. 3, pp. 223–231, 2005
47. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours
    Cancer Chemotherapy and Pharmacology, vol. 55, no. 2, pp. 117–128, 2004
48. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
    Cancer Chemotherapy and Pharmacology, vol. 55, no. 4, pp. 379–386, 2004
49. Gastrointestinal stromal tumours(Br J Surg 2003; 90: 1178- 1186)
    British Journal of Surgery, vol. 91, no. 1, pp. 126–126, 2004
50. Treatment of Uterine Sarcoma at the Royal Marsden Hospital from 1974 to 1998
    Clinical Oncology, vol. 16, no. 4, pp. 261–268, 2004
51. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 40, no. 5, pp. 689–695, 2004
52. In relation to Anninga et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas
    European Journal of Cancer, vol. 40, no. 7, pp. 924–925, 2004
53. A phase II study of ET-743/trabectedin (?Yondelis') for patients with advanced gastrointestinal stromal tumours
    European Journal of Cancer, vol. 40, no. 9, pp. 1327–1331, 2004
54. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    The Lancet, vol. 364, no. 9440, pp. 1127–1134, 2004
55. Systemic therapy of soft tissue sarcoma: an improvement in outcome
    Annals of Oncology, vol. 15, no. suppl_4, pp. iv193–iv196, 2004
56. A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas
    Cancer Research, vol. 64, no. 20, pp. 7201–7204, 2004
57. Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy
    Clinical Cancer Research, vol. 10, no. 11, pp. 3863–3870, 2004
58. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours
    British Journal of Cancer, Article ID 6602178, 2004
59. Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
    British Journal of Cancer, Article ID 6602196, 2004
60. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy
    Annals of Surgical Oncology, vol. 11, no. 5, pp. 465–475, 2004
61. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
    British Journal of Radiology, vol. 76, no. suppl_1, pp. S87–S91, 2003
62. Imatinib Mesylate
    Drugs, vol. 63, no. 5, pp. 523–524, 2003
63. Metastatic Soft Tissue Sarcoma in Adults
    American Journal of Cancer, vol. 2, no. 3, pp. 211–221, 2003
64. The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
    Current Cancer Drug Targets, vol. 3, no. 5, pp. 385–390, 2003
65. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling
    British Journal of Cancer, vol. 88, no. 4, Article ID 6600766, 5 pages, 2003
66. A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
    British Journal of Cancer, vol. 88, no. 7, Article ID 6600854, 6 pages, 2003
67. Treatment of epithelioid sarcoma at the Royal Marsden Hospital
    Sarcoma, vol. 7, no. 3-4, pp. 149–152, 2003
68. Malignant Gastrointestinal Stromal Tumor: Distribution, Imaging Features, and Pattern of Metastatic Spread
    Radiology, vol. 226, no. 2, pp. 527–532, 2003
69. Epithelioid hemangioendothelioma and other vascular mediastinal tumors: a role for alpha-2a interferon?
    The Annals of Thoracic Surgery, vol. 76, no. 2, p. 653, 2003
70. Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial
    Journal of Chromatography B, vol. 785, no. 1, pp. 175–186, 2003
71. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics
    European Journal of Cancer, vol. 39, no. 4, pp. 532–540, 2003
72. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
    European Journal of Cancer, vol. 39, no. 14, pp. 2006–2011, 2003
73. Uterine sarcoma: twenty-seven years of experience
    International Journal of Radiation OncologyBiologyPhysics, vol. 57, no. 5, pp. 1366–1373, 2003
74. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
    European Journal of Cancer, vol. 39, no. 1, pp. 64–69, 2003
75. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005)
    Cancer Chemotherapy and Pharmacology, vol. 51, no. 1, pp. 58–66, 2003
76. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
    European Journal of Cancer, vol. 38, no. 18, pp. 2397–2406, 2002
77. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
    European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002
78. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 38, no. 4, pp. 556–559, 2002
79. Mediastinal hemangioma: Successful treatment by alpha-2a interferon and postchemotherapy resection
    Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 2, pp. 404–406, 2002
80. A guideline for the management of gastrointestinal stromal tumour (GIST)
    Sarcoma, vol. 6, no. 3, pp. 83–87, 2002
81. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma a study by the EORTC Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 37, no. 7, pp. 870–877, 2001
82. STI571 a magic bullet?
    European Journal of Cancer, vol. 37, no. 15, pp. 1816–1819, 2001
83. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
    The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001
84. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation
    Cancer Chemotherapy and Pharmacology, vol. 49, no. 1, pp. 1–6, 2001
85. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
    European Journal of Cancer, vol. 36, no. 7, pp. 881–888, 2000
86. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
    Oncogene, vol. 19, no. 36, pp. 4125–4133, 2000
87. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 36, no. 1, pp. 61–67, 2000
88. Anti-Cancer Drugs, vol. 11, no. 6, pp. 433–437, 2000
89. New Developments and Approaches in the Platinum Arena
    Drugs, vol. 59, no. Supplement 4, pp. 29–36, 2000
90. Susceptibility of fibromatosis cells in short-term culture to ifosfamide: a possible experimental treatment in clinically aggressive cases
    Sarcoma, vol. 3, no. 2, pp. 79–84, 1999
91. Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    British Journal of Cancer, vol. 80, no. 11, pp. 1786–1791, 1999
92. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
    British Journal of Cancer, vol. 81, no. 6, pp. 1022–1030, 1999
93. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    European Journal of Cancer, vol. 35, no. 3, pp. 410–412, 1999
94. Investigational New Drugs, vol. 17, no. 1, pp. 49–56, 1999
95. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance
    Journal of Inorganic Biochemistry, vol. 77, no. 1-2, pp. 111–115, 1999
96. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide
    Cancer Chemotherapy and Pharmacology, vol. 44, no. 5, pp. 389–394, 1999
97. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous19F and31P probes
    NMR in Biomedicine, vol. 12, no. 8, pp. 495–504, 1999
98. Metabolism, excretion and pharmacokinetics of a single dose of [ 14 C]-raltitrexed in cancer patients
    Cancer Chemotherapy and Pharmacology, vol. 42, no. 1, pp. 71–76, 1998
99. Phase I study of oral JM216 given twice daily
    Cancer Chemotherapy and Pharmacology, vol. 42, no. 2, pp. 142–148, 1998
100. Annals of Oncology, vol. 8, no. 6, pp. 604–606, 1997
101. Annals of Oncology, vol. 8, no. 11, pp. 1099–1105, 1997
102. A pharmacokinetic and pharmacodynamic study In vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy
     European Journal of Cancer, vol. 33, no. 14, pp. 2418–2427, 1997
103. A phase I/II study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma
     Sarcoma, vol. 1, no. 3-4, pp. 149–154, 1997
104. ??Tomudex?? (raltitrexed) development: preclinical, phase I and II studies
     Anti-Cancer Drugs, vol. 8, no. Supplement 2, pp. S5–S9, 1997
105. Maturity in medical students
     The Lancet, vol. 347, no. 8993, pp. 55–56, 1996
106. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients
     Cancer, vol. 77, no. 4, pp. 675–682, 1996
107. Pre-clinical development of the anti-tumour agent CB 7646,BIS N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol
     International Journal of Cancer, vol. 68, no. 3, pp. 356–363, 1996
108. Pharmacokinetics of the13C labeled anticancer agent temozolomide detectedin vivo by selective cross-polarization transfer
     Magnetic Resonance in Medicine, vol. 34, no. 3, pp. 338–342, 1995
109. The role of the N-(hydroxymethyl)melamines as antitumour agents: Mechanism of action studies
     Biochemical Pharmacology, vol. 49, no. 9, pp. 1203–1212, 1995
110. Pharmacokinetic modelling—A prelude to therapeutic drug monitoring for all cancer patients?
     European Journal of Cancer, vol. 31, no. 11, pp. 1733–1735, 1995
111. Jaundice with ondansetron
     The Lancet, vol. 344, no. 8916, pp. 190–191, 1994
112. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines
     European Journal of Cancer, vol. 30, no. 12, pp. 1827–1836, 1994
113. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study
     European Journal of Cancer, vol. 30, no. 6, pp. 842–843, 1994
114. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitoR, ICI D1694, in mouse and human cultured cells
     Biochemical Pharmacology, vol. 45, no. 4, pp. 863–869, 1993
115. The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice
     Biochemical Pharmacology, vol. 46, no. 12, pp. 2229–2234, 1993
116. Poly(ADP-ribosylation) as target for cancer chemotherapy
     The Lancet, vol. 342, no. 8872, p. 632, 1993
117. High-performance liquid chromatographic assay for the measurement of the novel microtubule inhibitor 1069C85 in biological tissues and fluids
     Journal of Chromatography: Biomedical Applications, vol. 622, no. 2, pp. 243–248, 1993
118. Journal of Medicinal Chemistry, vol. 36, no. 26, pp. 4195–4200, 1993
119. Phase II studies: Wrong doses, wrong patients?
     European Journal of Cancer and Clinical Oncology, vol. 27, no. 10, pp. 1198–1200, 1991
120. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer
     European Journal of Cancer and Clinical Oncology, vol. 26, no. 7, pp. 824–827, 1990
121. Chronic high-dose pamidronate in refractory malignant hypercalcaemia
     The Lancet, vol. 335, no. 8692, p. 802, 1990
122. How many tests are required in the diagnosis of palpable breast abnormalities?
     Clinical Oncology, vol. 2, no. 3, pp. 148–152, 1990
123. INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
     The Lancet, vol. 334, no. 8668, pp. 879–882, 1989
124. Letter to the editors
     Cancer Chemotherapy and Pharmacology, vol. 20, no. 2, 1987
125. Multiple myeloma in a pair of monozygotic twins: the first reported case
     British Journal of Haematology, vol. 60, no. 3, pp. 551–554, 1985
126. A NEAR-DEATH EXPERIENCE
     The Lancet, vol. 322, no. 8349, pp. 561–562, 1983